Navelbine (Vinorelbine Tartrate)

Navelbine (vinorelbine tartrate) is used in oncology to target rapidly dividing cancer cells in specific solid tumours.

• Non‑small cell lung cancer: administered as part of first‑line or second‑line therapy to inhibit tumor progression.
• Metastatic breast cancer: used to reduce disease spread and improve survival outcomes.
• Combination regimens for NSCLC: incorporated with platinum‑based agents to enhance overall response rates.

• Vinorelbine tartrate binds to tubulin at the vinca binding site, preventing microtubule polymerisation. This disruption halts mitotic spindle formation, leading to mitotic arrest and apoptosis of rapidly proliferating cancer cells. The drug’s activity is independent of hormone receptors and is primarily cytotoxic to dividing tumour cells.

Common Side Effects

• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: gastrointestinal upset often managed with anti‑emetics.
• Constipation: decreased bowel motility requiring dietary measures.
• Fatigue: persistent tiredness affecting daily activities.
• Alopecia: hair thinning or loss during treatment.
• Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophils requiring urgent medical care.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Pulmonary toxicity: shortness of breath or cough indicating lung involvement.
• Cardiac arrhythmias: irregular heart rhythm observed in susceptible patients.
• Hepatic dysfunction: elevated liver enzymes indicating liver stress.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for adverse events.

• Blood count monitoring: perform complete blood counts regularly to detect neutropenia.
• Hepatic function assessment: check liver enzymes prior to and during treatment.
• Cardiac evaluation: consider ECG in patients with known heart disease.
• Infection risk: avoid use in patients with active severe infections.
• Contraception: advise effective contraception during treatment and for a defined period after.
• Store at below 25°C: keep capsules in the original packaging, protect from moisture and direct sunlight.

Vinorelbine may interact with other medicines that affect its metabolism or increase myelosuppression.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise vinorelbine plasma levels and toxicity.
• Concurrent use with other myelosuppressive chemotherapy agents: can markedly increase risk of severe neutropenia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters as vinorelbine can alter bleeding risk.
• Drugs causing QT prolongation: observe cardiac rhythm when combined with agents that affect cardiac repolarisation.